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ABSTRACT 
Chronic inflammation is known to play a role in cancer initiation, promotion, 
and metastasis. However, the mechanism by which inflammation promotes metastasis is 
still unclear. We evaluated if chronic inflammation induced by autoimmune arthritis may 
contribute to increased breast cancer-associated metastasis. We report a three-fold 
increase in lung metastasis and a significant increase in the incidence of bone metastasis 
in the pro-arthritic mice compared to control mice. The metastatic breast tumors in turn 
augment the severity of arthritis resulting in a vicious cycle that increases both bone 
destruction and metastasis. Enhanced neutrophilic and granulocytic infiltration in lungs and 
bone of the pro-arthritic mice and subsequent increase in circulating levels of proinflammatory 
cytokines, such as IL-17, IL-6, VEGF, and TNF-α were the underlying factors contributing to the 
increased metastasis. The data clearly has important clinical implications for patients 
diagnosed with metastatic breast cancer.   
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INTRODUCTION 
Metastasis is regulated not only by intrinsic genetic changes in malignant cells, but also 
by the microenvironment. Several studies have demonstrated that sites of chronic 
inflammation are often associated with the establishment and growth of various 
malignancies 1. A common inflammatory condition in humans is autoimmune arthritis 
(AA) that causes inflammation and deformity of the joints. Other systemic effects 
associated with AA include increased cellular infiltration and inflammation of the lungs 
and blood vessels (vasculitis), and weakening of the bones (osteoporosis). Although AA 
and cancer are different diseases, some of the underlying processes that contribute to the 
disorders of the joints and connective tissue that characterize AA also affect cancer 
progression and metastasis. In addition, the immune system appears to play an overseer’s 
role in both diseases reviewed by Ziegler et al 2. The most striking link between the two 
diseases came from a long-term community-based prospective study of the influence of 
inflammatory polyarthritis (IP) in cancer incidence and survival 3. The authors reported 
that inflammatory arthritis increases the risk of dying from cancer (at least double the risk 
of general population). Several studies have also reported statistically significant risk 
ratios between AA and various malignancies including breast, lung, hematopoietic, non-
melanotic skin, kidney, and colon 4-6. 
 
Despite this knowledge available for a decade, there has been minimal research linking 
arthritis with metastatic breast cancer. It has never been questioned if a site of chronic 
inflammation linked to AA creates a milieu that attracts tumor cells to home and grow in 
the inflamed site. The lungs and bones are frequent sites of breast cancer metastasis 7. 
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The preference of breast cancer cells to grow in the bone and lung is underscored by the 
fact that 65-75% of patients with advanced disease develop bone or lung metastases 8. 
Yet, it is not known why and how breast cancer cells prefer to colonize these organs. 
There are no methods to predict the risk of breast cancer-associated metastasis and 
current treatments have notable limitations. We hypothesize that chronic inflammatory 
milieu and osteoclastic bone resorption caused by AA and the lung inflammation 
associated with it may influence the recruitment, retention, and proliferation of tumor 
cells in the bone and lungs.  
 
In this study, we determined if chronic inflammation in the bones and lungs induced by 
AA contribute to increased breast cancer-associated bone and lung metastasis. We have 
used a recently established animal model of spontaneous autoimmune arthritis known as 
the SKG mice. These mice are on the Balb/c background and carry a mutation of the gene 
encoding a SH2 domain of ZAP-70, a key signal transduction molecule in T cells and 
spontaneously develop T cell-mediated chronic AA 9. The mutation impairs positive and 
negative selection of T cells in the thymus, leading to thymic production of arthritogenic 
autoimmune CD4+ T cells. The mice succumb to symmetrical joint swelling beginning in 
the small joints of the digits and progressing to larger joints, accompanied by severe 
synovitis with formation of pannus invading and eroding adjacent cartilage and 
subchondral bone. Genetic deficiency of IL-6, IL-1, or TNF-α inhibit development of AA 
in SKG mice 10, similar to the effects of anticytokine therapy in human arthritis 11. These 
clinical and immunopathological characteristics of AA in these mice make the strain a 
suitable model for testing our hypothesis. When these arthritic mice were induced to 
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develop metastatic mammary gland tumors, a significant increase in lung and bone 
metastasis were observed compared to the non-arthritic mice. Furthermore, the severity 
of arthritis was amplified by factors-associated with the metastatic compared to the non-
metastatic tumor cells. We identified the key pro-inflammatory factors that contribute to 
the increased incidence of secondary metastasis and to the severity of the bone disease. A 
novel link between AA-induced inflammation and secondary metastasis is established. 
 
RESULTS 
 
Metastatic breast cancer cells contribute to the severity of arthritis in the SKG mice 
In pathogen-free facilities, the SKG mice remain pro-arthritic with no macroscopic signs 
of joint swelling until treated zymosan A (a yeast cell wall extract) 12. Within 30-45 days 
post zymosan treatment, macroscopic evidence of joint swelling in the fingers and in the 
fore and hind limbs is evidenced (Fig 1. a-f). SKG, SKG + zymosan (30-days post 
treatment) and Balb/c control mice were challenged with 1x106 syngeneic breast cancer 
cells (4T1 being metastatic and TUBO being non-metastatic) in the mammary fat pad. 
Compared to the Balb/c control and the pro-arthritic SKG mice (Fig 1. a and b), the joint 
swelling was 5-fold higher in the 4T1 tumor-bearing SKG + zymosan mice (Fig 1. e and 
f) and 2-fold higher in the TUBO-bearing SKG + zymosan  mice (Fig 1. c and d). The 
SKG + zymosan mice bearing the 4T1 tumors had a 2-fold increase in joint swelling 
compared to the same mice bearing the TUBO tumors (Fig 1. e and f compared to Fig 1. 
c and d) suggesting that the metastatic 4T1 breast cancer cells can augment the severity 
of arthritis. Similar results were seen in N=8 mice per experimental group.  
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Although SKG mice bearing the 4T1 or TUBO tumors did not show signs of joint 
swelling, histological examination of the bone sections clearly indicate severe 
inflammation with high degree of cellular infiltration in the joints of the 4T1 tumor-
bearing SKG mice but not in the TUBO-bearing SKG mice (Fig 1. l and j). Similarly, 
higher severity of synovial hyperplasia and erosion of articular cartilage in the phalangeal 
joints of the hind limb along with severe cellular infiltration was found in the 4T1 tumor-
bearing SKG + zymosan mice (Fig 1. m) compared to the joints of the TUBO-bearing 
SKG + zymosan mice (Fig 1. k). Thus, it becomes clear that the metastatic 4T1 but not 
the non-metastatic TUBO breast cancer cells contribute to the vicious cycle of osteolytic 
destruction. Inflammation was not observed in zymosan-treated Balb/c mice or in saline-
treated SKG mice (Fig 1. g and h). Several sections from N=8 mice per experimental 
group were examined with similar results. Sections of the distal hind limb joints are 
shown.  
 
Significantly higher primary breast tumor burden in pro-arthritic SKG mice as 
compared to the non arthritic Balb/c mice 
Next we questioned if the primary tumor burden is affected by the pro-arthritic or 
arthritic milieu. The 4T1 and TUBO tumor burden in the SKG mice was significantly 
higher compared to the non arthritic Balb/c mice (Fig 1. n and o **p<0.01). Surprisingly, 
this was reversed in the SKG + zymosan mice where the primary 4T1 or TUBO tumor 
weight remained exactly the same as the tumor weights in the Balb/c control mice (Fig 1. 
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n and o). The data may indicate that the innate immune responses elicited by zymosan 
injection might regulate the primary tumor growth.  
 
Significant increase in lung metastasis in the pro-arthritic and arthritic mice. 
We observed a 3-fold increase in the incidence of lung metastasis in the 4T1 tumor-
bearing SKG and SKG + zymosan mice compared to the 4T1 tumor-bearing Balb/c mice 
(Fig 2. a-j and Table 1. a-c). One hundred percent of the SKG (8/8 mice) and SKG + 
zymosan (9/9 mice) mice developed lung metastasis with the 4T1 tumors compared to 
only 27% (3/11 mice) of the Balb/c mice (Fig 2. j and Table 1. a-c). The number and size 
of the lung lesions were also found to be significantly higher in the SKG versus the 
Balb/c mice (Table 1. a-c). This result is especially significant since it represents true 
metastasis arising from the primary mammary gland tumor. Lungs from TUBO-
challenged mice show no metastatic lesions in the Balb/c or SKG mice, albeit 2/8 SKG + 
zymosan mice developed lung lesions (Fig 2. d-f and Table 1. d). There were no 
metastatic lesions in lungs of control Balb/c, SKG, and SKG-zymosan mice without 
tumor challenge (Fig 2. a - c, and j). A representative lung from each experimental group 
is shown (Fig 2. a - i).  
To investigate a mechanism of the increased lung metastasis, we first examined the lung 
histology. It became apparently clear that all lungs that developed metastasis were packed 
with inflammatory cellular infiltrates characterized by prominent neutrophilic and 
granulocytic cells and activated macrophages (Fig 2. n-w). We graded the severity of 
lung infiltration and arbitrarily assigned levels of infiltration as ‘no’, ‘low’, ‘medium’, 
and ‘high’. Table 1 shows a strong correlation between the level of lung infiltration and 
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severity of lung metastasis in all mice. Along with the cellular infiltrates, epithelial 
metastatic lesions were identified in the lungs as indicated by the solid yellow 
arrowheads (Fig 2. s, t, u, and w). The lungs from SKG (Fig 2. n), SKG + zymosan (Fig 
2. o), TUBO-bearing Balb/c (Fig 2.p), TUBO-bearing SKG (Fig 2.q), and TUBO-bearing 
Balb/c + zymosan (Fig 2. r), all show normal architecture and correlates with zero lung 
lesions (Table 1). A high degree of correlation exists between level of cellular infiltration 
in the lungs and lung metastasis suggesting a chemo-attractant microenvironment created 
in the lungs of arthritic mice for breast cancer cells to home and grow. Correlation 
Coefficient for lung infiltration and development of lung metastasis was calculated to be 
0.99. 
The next obvious question was whether the severity of lung metastasis follows the 
severity of arthritis. A representative lung and bone section of a 4T1 tumor-bearing SKG 
mouse is shown in Fig 2. k and l in which severe inflammation in the fore and hind limbs 
correlated with severe metastatic lung lesions. Significant correlation exists between 
severity of joint inflammation and the development of lung metastasis in the 4T1 tumor-
bearing SKG and SKG + zymosan mice (correlation coefficient of 0.93 and 0.90) (Fig 2. 
m).  
 
Increased expression of pancytokeratin positive epithelial cells in the arthritic bones 
coupled with increased expression of CD31 and COX-2. 
Since cellular infiltration in the lungs greatly facilitated the recruitment of breast cancer 
cells to the site (Fig 2.), we examined if high cellular infiltration in the bones of the 
arthritic mice had a similar effect. We have already established that there is increased 
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cellular infiltration in the bones of arthritic mice challenged with the 4T1 tumors (Fig 1. l 
and m). We now examined the levels of pro-inflammatory factors in the bone that may 
create a milieu conducive for increased bone metastasis. Inflammation in the joints is 
usually represented by high levels of cyclooxygenase-2 (COX-2) expression which plays 
a critical role in fostering tumor growth. In the same context, increased platelet 
endothelial cell adhesion molecule (CD31) expression in the bone correlates with tumor 
cell homing and spreading. In comparison to the non tumor-bearing arthritic mice, the 
expression of COX-2 and CD31 in the bones of the 4T1 tumor-bearing arthritic mice was 
significantly greater (Fig 3. a – f for COX-2 and g - l for CD31). In contrast, the 4T1 
tumor-bearing non-arthritic Balb/c and Balb/c + zymosan mice had minimal expression 
of the two proteins (Fig 3. a and c). Thus, we hypothesize that the pro-inflammatory 
microenvironment in the arthritic bone enhances the metastatic potential of the 4T1 
tumors and that the 4T1 tumors in turn augment the severity of inflammation in the bone 
which creates a highly conducive microenvironment for the 4T1 tumors to home and 
proliferate. To directly test the presence of epithelial (tumor) cells in the inflamed bones, 
sections of the bone were stained with pan-cytokeratin antibody. Increased expression of 
pancytokeratin-positive areas was only evident in the bones of the 4T1 tumor bearing 
arthritic mice (Fig 3. n and p). Bones from all other experimental groups were negative 
(Fig 3. m, o, q, and r). Brown staining represents CD31, COX-2, and pancytokeratin 
positivity. Bones from n=8 mice were examined with similar staining patterns.  
 
Increased 4T1 bone lesions in the arthritic versus non-arthritic mice  
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The bones from n = 4 - 5 mice were analyzed by Faxitron imaging for osteolytic lesions. 
Representative images are shown in Fig 3. s - x. Osteolytic and/or sclerotic bone lesions 
were determined in ~50% (2/4) of SKG mice and 60% (3/5) of the SKG + zymosan mice 
challenged with the 4T1 metastatic tumor cells (Fig 3. v and w). These bones show 
distinct radiolucencies in the distal femoral diametaphysis indicating apparent osteolytic 
bone lesion (as indicated by the arrows). In contrast, none of the Balb/c mice challenged 
with 4T1 tumors developed bone lesions (Fig 3. t) nor did any of the SKG mice 
challenged with TUBO cells (Fig 3. s, u, and x). The results confirm that bone lesions 
only occur in the pro-arthritic bones but not in non-arthritic bones (Fig 3. y). 
 
M-CSF, IL-6, IL-17, TNF-α and VegF may be the underlying factors responsible for 
the increased metastasis in the arthritic mice. 
To determine the possible mechanism that drives the 4T1 cells to become more 
metastatic in the arthritic model, we evaluated the circulating levels of pro-inflammatory 
cytokines and chemokines in the sera of the arthritic versus the non-arthritic mice. A 
custom mouse cytokine array was designed to test the sera for the presence of 10 
cytokines known to be associated with AA, inflammation, and metastasis. These included 
macrophage colony stimulating factor (M-CSF), tumor necrosis factor-alpha (TNF-α), 
Interferon-gamma (IFN-γ), VegF, Interleukin-17 (IL-17), matrix metalloproteinase-2 
(MMP-2), Interleukin-6 (IL-6), Insulin-like growth factor-II (IGF-II), Interleukin-1beta 
(IL-1β), and Interleukin-4 (IL-4) (Fig 4. a). Compared to the 4T1 tumor-bearing Balb/c 
mice, significant increase in the levels of M-CSF (1.5 fold), IL-17 (1.3 fold), TNF-α, 
VegF and IL-6 (1.2 fold) was observed in the 4T1-bearing arthritic mice (Fig 4. e-g,). A 
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graphical representation of the values from the densitometric analysis is provided in Fig 
4. h. In the TUBO-bearing mice, the increase was non-significant (Fig 4. b-d and h), once 
again implying that the increase in the cytokine levels were driven by a combination of 
the metastatic 4T1 tumors and AA but not by either condition alone.  
 
DISCUSSION 
 
A significant increase in breast cancer-associated secondary metastasis is observed in the 
arthritic versus the non-arthritic mice (Fig. 2 and 3). In addition, the metastatic breast 
cancer cells accentuate the severity of bone and lung inflammation in the arthritic mice 
creating a favorable microenvironment for the tumor cells to grow (Fig 1 and 2). We 
establish that the chronic inflammation in the bone and lung caused by AA and the 
subsequent increase in circulating levels of proinflammatory cytokines may be the 
underlying mechanism for the increased metastasis (schematically represented in Fig 5.). 
Metastatic breast cancer cells produce factors that directly or indirectly induce the 
formation of osteoclasts. In turn, bone resorption by osteoclasts releases growth factors 
from the bone matrix that stimulate primary tumor growth, and bone destruction. This 
reciprocal interaction between breast-cancer cells and the bone microenvironment results 
in a vicious cycle that increases both bone destruction and increases tumor burden and 
metastasis (Fig 5.) 13. The fact that the primary tumor burden is not increased in the SKG 
mice injected with zymosan (Fig 1. n and o) can be explained by the fact that zymosan, a 
crude yeast cell wall extract activates the arthritogenic T cells through stimulating the 
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innate immune response 12, which helps keep the primary tumor in check but does not 
reduce the incidence of metastasis.  
 
The lungs of the arthritic mice with the 4T1 metastatic lesions express exceptionally high 
levels of interstitial inflammatory cellular infiltrates characterized by prominent 
neutrophils, mast cells, activated macrophages, and possibly eosinophils (Fig 2. n-w).  
These pro-inflammatory leukocytes alone can facilitate tumor cell extravasation and 
promote metastasis 14. This is the first study that undoubtedly establishes a correlation 
between the pro-inflammatory cell recruitment in the lungs during AA and the homing of 
the circulating tumor cells in the inflamed lungs (Figure 2 and Table 1).  
 
As in human AA, cytokines play an essential role in the development of arthritis in the 
SKG mice 9, 15. Several cytokines have been implicated in the mechanism of synovial cell 
activation and joint destruction in AA 16. In our study, serum analysis of cytokine 
proteins revealed higher expression of M-CSF, IL-17, IL-6, TNF-α, and VegF in the 
arthritic mice only when challenged with 4T1 metastatic breast cancer cells (Fig 4). 
Elevated serum M-CSF predicts reduced survival in metastatic breast cancer patients. The 
M-CSF produced by breast cancer cells and surrounding stoma increases osteoclast 
formation and maturation and enhances the expression of stromal RANK ligand, both of 
which increase osteolytic bone degradation 17. IL-17 has been identified as a crucial 
cytokine for osteoclastic bone resorption in AA patients. IL-17 acts on osteoblasts by 
stimulating COX-2–dependent prostaglandin E2 (PGE2), and osteoclast differentiation 
factor which differentiates osteoclast progenitors into mature osteoclasts, causing bone 
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resorption. PGE2 interacts with its eicosanoid receptors to induce the damage 18. IL-6 is 
an autocrine and paracrine growth factor for several cancers, including breast cancer 19 
and stimulates cancer cell growth and contributes to recurrence and metastasis in breast 
cancer 20. VegF is known to play a critical role in vasculogenesis, angiogenesis, and 
metastasis. Upregulation of these cytokines may therefore account for the enhanced 
breast cancer associated secondary metastasis as well as accentuating the severity of 
arthritis in the SKG mice. Thus, blocking these pro-inflammatory cytokines may hold 
promise in reducing the severity of both diseases. 
 
Inflammation is a critical hallmark of arthritis and tumor progression 2, 21-23. Many 
processes that occur during arthritis also occur during tumorigenesis. There is increased 
vascularity in both; and there are common cytokines and growth factors that are regulated 
in both. The microenvironment in the tumor and arthritis is largely orchestrated by 
inflammatory cells 24. Thus, it is not unlikely that the two diseases commonly co-exist in 
women. Our study begins to evaluate whether these two disease states molecularly 
interact and feed of each other. These studies may have important clinical implications, 
especially in the prevention of secondary metastasis, in designing combination drug 
regimens, and as a diagnostic risk-assessment tool. 
 
METHODS 
 
Mice 
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SKG mice have been established from the closed breeding colony of Balb/c mice 9. Two 
sets of SKG breeding pairs were purchased from CLEA International Japan and were 
maintained in our animal facility. All protocols were approved by the Mayo Clinic 
Internal Animal Care Review Committee. 
 
Induction of Arthritis 
Two month old mice were given a single intraperitoneal (ip) injection of 2mg of zymosan 
A in 100ul of 0.15M NaCl per mouse 12 and joint swelling was macroscopically 
examined starting at 14-days post zymosan A treatment. Thirty days post zymosan A, 
>95% of the mice develop polyarthritis in small and large joints. At this time, mice were 
injected with 1x106 (in 100ul of phospahate buffered saline) syngeneic breast cancer cells 
(4T1: metastatic or TUBO: non-metastatic) in the mammary fat pad. Age-matched SKG 
mice without zymosan A were used as the pro-arthritic model, and Balb/c mice were used 
as the non-arthritic controls. Tumors were allowed to grow for 4 weeks. Zymosan A was 
purchased from Sigma-Aldrich, USA. A 1% solution of zymosan was made in 0.15 M 
sodium chloride (NaCl), placed in boiling water bath for one hour, centrifuged for 30 
minutes at 4000 rpm and the residue suspended evenly in the 0.15M NaCl to the desired 
concentration. It is established that the glucose polymer B-1,3-D-glucans (B-glucans), the 
main constituents of zymosan A, are responsible for the arthritogenic effect (12). 
 
Cell Culture 
The 4T1 mammary carcinoma cell line was purchased from The American Type Cell 
Culture Collection and the TUBO mammary carcinoma cell line was generously provided 
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by Dr Joseph Lustgurten, Mayo Clinic College of Medicine. 4T1 and TUBO cells were 
maintained in RPMI-1640 medium supplemented with 10% FBS, 1% Glutamax-1 and 
1% penicillin-streptomycin. Cells were maintained at log phase at 370C with 5% carbon 
dioxide. 4T1 is a highly metastatic breast cancer cell line derived from a spontaneously 
arising BALB/c mammary tumor. TUBO is a cloned cell line established from a 
mammary carcinoma of the Her2-neu transgenic mice also on the Balb/c background. 
TUBO is considered to be a non metastatic cell line. 
 
Measurement of Circulating Cytokines  
The RayBio® Custom Mouse Cytokines Antibody Array kit was purchased from 
RayBiotech (Norcross, GA) and used according to the manufacturer’s instructions. 
Briefly, after blocking with 1X blocking buffer (provided by the manufacturer), 
membranes were incubated for 1.5h with the experimental serum (10-fold diluted with 
1X blocking buffer). The membranes were washed and incubated with biotin-conjugated 
antibodies for 1.5 h. The membranes were washed again and incubated with streptavidin-
conjugated horseradish peroxidase (HRP) for 2h, washed, and developed using an 
enhanced chemiluminescent substrate for HRP. Chemiluminescence was detected using a 
EpiChemi3® Darkroom imaging system and LabWorks® densitometry software (both 
from UVP Bioimaging, Upland, CA).  Data was corrected for background signal and 
normalized to positive controls using RayBio® Analysis Tool software. 
 
Histology 
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Lungs and a part of the tumor were formalin fixed in 10% neutral-buffered formalin (pH 
6.8-7.2) for a minimum of 24 hours. Paraffin embedded blocks were prepared by the 
Histology Core at The Mayo Clinic and 4-micron thick sections were cut for hematoxylin 
eosin (H&E) staining and for immuno-staining. For bones: The fore limb and hind limb 
were dissected from the mice and immersed in 10% neutral-buffered formalin (pH 6.8-
7.2) overnight. For decalcification, Cal-Rite (Richard Allan Scientific, Kalamazoo, MI), a 
formic acid decalcification agent was used for ~72 hours followed by the conventional 
processing method. To determine CD31, COX-2 and Pancytokeratin expression in the 
bones, COX-2, CD-31, and  Pancytokeratin (Santa Cruz Biotechnologies) antibodies 
were used at 1:50 and incubated overnight at 4◦C followed by the DAKO anti-goat 
secondary (1:100 dilution) for 45 minutes at RT for both COX-2 and CD-31. For 
Pancytokeratin staining, DAKO anti-mouse secondary was used at 1:100 for 45mins at 
RT. 3, 3” –Diaminobenzidine was used as the chromogen and hematoxylin was used as 
counterstain. Slides were examined under light microscopy and pictures taken at 200X 
magnification. 
 
Faxitron Imaging: The Faxitron is a 160-kVp x-ray machine that was adapted from an 
x-ray imaging unit through modifications to facilitate experimental irradiation and 
imaging. The Faxitron model CP160 (Faxitron X-Ray Corp., Wheeling, IL, USA) is a 
commercially available x-ray tube machine that is designed for animal irradiation 25. The 
analysis was conducted by a Mayo Clinic Radiologist. 
 
Statistical analysis: 
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Student’s t-test was used for comparing the level of significance between the 
experimental groups. Correlation Coefficient was determined using the JMP statistical 
program. 
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FIGURE LEGENDS 
 
Figure 1. Induction of arthritis and tumor burden in SKG mice: a-f: Images of the 
hind and fore limbs a: control Balb/c mice (no inflammation); b: control SKG mice (no 
inflammation); i: control SKG + zymosan without tumor challenge (moderate 
inflammation);  c and d: SKG mice + zymosan A + TUBO (low-level inflammation); e 
and f: SKG mice + zymosan A + 4T1 cells (severe swelling). g-m: H&E staining of 
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sections from the joints: g: Balb/c mice; h: SKG mice; j: SKG mice + TUBO cells; k: 
SKG mice + zymosan A + TUBO cells showing some erosion of articular cartilage; l: 
SKG mice + 4T1 cells showing severe inflammation in the phalangeal joints; and m: 
SKG mice + zymosan A + 4T1 cells showing severe synovial hyperplasia and erosion of 
articular cartilage and bone in phalangeal joints with severe inflammation; n-o: Tumor 
burden in grams (g)n: mice injected with 4T1 cells; o: mice injected with TUBO cells. 
Compared to the non-arthritic Balb/c mice, a significant increase in tumor burden was 
observed in SKG mice with 4T1 (**p<0.01) and TUBO cells (*p<0.05). Note: All tumor 
cells were injected in the mammary fat pad and sacrificed 4-weeks post tumor challenge. 
All images taken at 200X magnification 
 
Figure 2. AA-related inflammation in the lungs is associated with a 3-fold increase 
in the number of lung metastatic lesions in the SKG mice. Representative images of 
lungs from a: Balb/c; b: SKG; c: SKG + zymosan A; d: Balb/c injected with TUBO 
cells; e: SKG without zymosan A + TUBO cells; f: SKG + zymosan A + TUBO cells 
(2/8 mice developed lung lesions); g: Balb/c + 4T1 cells (3/11 mice developed lung 
lesions); h: SKG without zymosan A + 4T1 cells (8/8 mice developed severe lung 
metastasis); i: SKG + zymosan A + 4T1 cells (9/9 mice developed severe lung 
metastasis). j: Percent mice that developed lung metastasis. k and l: H&E of bone 
section showing high inflammation and an image of lung with metastasis from the same 
4T1-bearing SKG mouse. m: A statistical analysis for correlation of bone inflammation 
and lung metastasis. The correlation coefficient for the 4T1 tumor-bearing SKG and SKG 
+ zymosan mice was determined to be 0.93 and 0.90. Correlation for TUBO-bearing mice 
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was not calculated.  n-w: H&E staining of the lung sections from n: SKG (no 
infiltration); o: SKG + zymosan A (moderate infiltration).p: Balb/c + TUBO; q: SKG + 
TUBO; r: Balb/c + zymosan A + TUBO; s: SKG + zymosan A + TUBO (high 
infiltration); t: Balb/c + 4T1 (high infiltration due to the 4T1 cells, representative of the 
mice that had lung metastatic lesion); u: SKG + 4T1 (severe infiltration); v: Balb/c + 
zymosan A + 4T1 (no infiltration); and w: SKG + zymosan A + 4T1 (severe infiltration). 
The solid filled arrow represents lung metastatic lesions, unfilled arrow represents 
neutrophils and unfilled circles represent macrophages. All images taken at 200X 
magnification 
 
 
Figure 3. Increased expression of COX-2, CD31, and pancytokeratin in the bones of 
arthritic mice challenged with 4T1 cells. Bone sections from various experimental 
groups (indicated in the Figure) stained for COX-2 (a-f), CD31 (g-l), and pancytokeratin 
(m-r). Brown staining represents positive staining.  All images taken at 200X 
magnification. Representative Faxitron images of bones (s-x). Balb/c + TUBO (s); Balb/c 
+ 4T1 (t); SKG + TUBO (u); SKG + 4T1 (v) showing a few small radiolucencies in 
distal femoral diametaphysis indicating apparent osteolytic bone lesion;  SKG + zymosan 
A + 4T1 (w) showing a medium size poorly defined radiolucency in the distal femoral 
diametaphysis possibly due to osteolytic bone lesion; and SKG+ Zymosan+ Tubo (x). 
N=4-5 mice from each group were examined using the faxitron. No lytic or sclerotic 
lesions were observed in any other experimental group. y: Percent mice that developed 
bone metastasis. 
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Figure 4. Serum analysis of cytokines revealed upregulation of several cytokines in 
the arthritic mice. 
a. Array template of the cytokines on the membrane. b-g. Membrane dot blot 
representing circulating cytokine levels in various groups of mice (indicated in the 
Figure). Boxes are drawn around the cytokines that are up-regulated. h: A graphical 
representation of the up-regulated cytokines observed on the membrane blots based on 
densitometric analysis. Up-regulation of M-CSF, TNF-alpha, IL-17, VegF, and IL-6 is 
observed and highlighted in gray on the template (a).  
 
Figure 5: Schematic model representing the vicious interaction between metastatic 
breast tumors and the inflammatory microenvironment in the bone and lung due to 
AA: During arthritis, neutrophils, and macrophages infiltrate the bones and lungs causing 
high degree of inflammation which trigger the release of pro-inflammatory cytokines 
(such as IL-17, IL-6, TNF-α, and VegF) in the circulation. These cytokines act directly or 
indirectly on the primary breast tumor cells enhancing their metastatic ability. In turn, the 
metastatic 4T1 breast tumor cells release more pro-survival/pro-inflammatory cytokines 
and invade the underlying extracellular matrix and circulate in the blood and lymphatic 
systems of the arthritic mice. The large amounts of inflammatory cells and pro-
inflammatory cytokines in the bones and lungs attract the tumor cells to leave the 
circulation and enter the organs. In the bone, the tumor cells stimulate the release of IL-
17 which differentiates osteoclast progenitors into mature osteoclasts, causing bone 
resorption. The damage to the bone matrix allows retention and growth of the tumor cells 
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in the site. The tumor cells also stimulate the surrounding stromal cells to release M-CSF 
which increases osteoclast formation and maturation which increases osteolytic bone 
degradation and creates a milieu suitable for tumor cells to form metastatic lesions. In the 
lungs, the infiltrating cells and the tumor cells release M-CSF, TNF-α, IL-6 and VegF 
stimulating vasculogenesis, angiogenesis and tumor growth. The final distribution of 
metastasis reflects the relative abundance of inflammation in the organs. Thus, we 
hypothesize that the increase in circulating levels of proinflammatory cytokines is the underlying 
factor responsible for the increased metastasis.  
 
TABLE 1: High cellular infiltration in the lungs correlates with an increase in the 
number of lung metastatic lesions in the arthritic mice. 
Number of lung lesions in non-arthritic Balb/c (a) and arthritic mice (b and c) challenged 
with 4T1 cells (a-c) or TUBO cells (d). Size and number of lung lesions are shown along 
with level of infiltration in the same lungs. High degree of correlation exists between cellular 
infiltration and metastatic lung lesions. 
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Table 1 
Group  Mice # 
Infiltrating cells in the 
lungs  
(High/Medium/Low) Size of Lung Lesions 
# Lung 
Lesions
      Large Medium Small Total  
(a)  Balb/c+4T1(3/11) 1 No 0 0 0 0 
  2 No 0 0 0 0 
  3 No 0 0 0 0 
  4 No 0 0 0 0 
  5 No 0 0 0 0 
  6 Low 8 0 9 17 
  7 No 1 0 0 1 
  8 No 0 0 0 0 
  9 No 0 0 0 0 
  10 No 0 0 0 0 
  11 No 0 0 2 2 
(b)  SKG+4T1(8/8) 1 High 16 0 9 25 
  2 High 10 0 11 21 
  3 High 0 22 0 22 
  4 High 15 0 5 20 
  5 High 2 0 10 12 
  6 High 0 0 13 13 
  7 Medium 0 0 9 9 
  8 High 0 0 14 14 
(c) SKG+zymosan+4T1(9/9) 1 Medium 0 3 0 3 
  2 Medium 2 0 4 6 
  3 High 10 0 9 19 
  4 Low 0 0 0 3 
  5 Medium 0 0 0 5 
  6 Medium 0 0 5 5 
  7 Medium 0 1 7 8 
  8 High 9 0 9 18 
  9 High 0 10 6 16 
(d) Balb/c+Tubo(0/7) No lesions No         
     SKG+Tubo(0/10) No lesions No         
    SKG+zymosan+Tubo(2/8) 1 Low 0 0 0 0 
  2 Low 0 0 0 0 
  3 Low 0 0 0 0 
  4 Low 0 0 0 0 
  5 Low 0 0 0 0 
  6 Low 0 0 0 0 
  7 Medium 0 10 0 10 
  8 Medium 0 4 0 4 
 
